-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Psoriasis is a common immune-mediated disease affecting approximately 2% of the global populati.
Worldwide, tuberculosis (TB) positivity conversion rates have been reported in psoriasis patients treated with biologics, particularly in regions with low tuberculosis ri.
Methods: Patients admitted to West China Hospital of Sichuan University from April 2019 to February 2021 were select.
Results: In the adalimumab group, 5 patients (43%) had tuberculosis negative, and 2 of them developed active tuberculosis within the first 6 mont.
Conclusions: Our data showed that among these psoriasis patients, TB conversion rates were relatively high after a mean course of 113 mont.
We recommend reassessment for tuberculosis after the initial 3 months in patients receiving adalimumab and then semiannual monitoring for the next two yea.
Source: Xiao Y, Chen H, Zou Q The Tuberculosis Positive Conversion Rate Among Psoriasis Patients Treated with Adalimumab and Secukinumab: A Single-Center Retrospective Study in Chi.
leave a message here